AEON Biopharma, Inc. shares news about FDA's feedback on its biosimilar product ABP-450.

Good for AEON

AEON's FDA meeting minutes support its proposed ABP-450 study plan, moving the Botox biosimilar program forward. The FDA still wants stronger study checks, and more evidence may be needed before approval.

AEON · AEON Biopharma, Inc.

AI read · Good for AEON

The AI's read

This gives AEON a clearer next step for testing ABP-450, not an approval. Earlier studies may help only after scientific comparisons connect them to U.S.-licensed Botox and today's ABP-450. The FDA asked for a study able to detect meaningful differences. More evidence may be needed after the full package is reviewed. AEON plans to send that package in 2027 and does not plan a separate comparison study now. The minutes also trigger the milestone warrants' expiration on November 16 unless exercised. That is a financing detail, not an FDA finding that ABP-450 is similar to Botox.

Get alerts for AEON

Follow AEON Biopharma, Inc. (AEON) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AEON

Free on the App Store and Google Play, or on the web.